Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Journal of Cancer Research and Clinical Oncology|September 27, 2018
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerGary Altwerger, Esther B Florsheim, Gulden Menderes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu ExpressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Gynecologic Oncology|May 6, 2017
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Gynecologic Oncology|August 10, 2021
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neuJoan Tymon-Rosario, Eric R Siegel, Stefania Bellone, et al.
Gynecologic Oncology Reports|November 18, 2020
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based studyEmily M Webster, Ghanshyam S Yadav, Stefan Gysler, et al.
Gynecologic Oncology|July 1, 2020
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinomaElena Bonazzoli, Stefania Bellone, Luca Zammataro, et al.
Scientific Reports|January 24, 2020
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecanBurak Zeybek, Aranzazu Manzano, Anna Bianchi, et al.
Frontiers in Oncology|March 3, 2020
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian CancerEmanuele Perrone, Salvatore Lopez, Burak Zeybek, et al.
Molecular Oncology|January 1, 2020
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivoEmanuele Perrone, Paola Manara, Salvatore Lopez, et al.
British Journal of Cancer|June 29, 2016
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoEmiliano Cocco, Salvatore Lopez, Jonathan Black, et al.
Pageof 8